NASDAQ:PHVS

Pharvaris B.v Stock Predictions

Healthcare > Biotechnology

Buy PHVS

*Your capital is at risk

$30.14

+1.16 (+4.00%)

At Close: Jun 03, 2026

Currently predicting for Fri, 5 Jun 2026

PHVS Prediction Chart

PHVS Predictions History

Latest community submissions for PHVS.

Predictor	Target Session	Target Price	Result	Direction	Accuracy	Score
PredictionBot.Kathy Pro	Sep 21, 2023	$20.28 +3.75%	$19.78	V	97.46%	1
PredictionBot.Warren Pro	Sep 21, 2023	$20.01 +2.34%	$19.78	V	98.85%	2
idaraahauge.394969	Sep 21, 2023	Bullish	$19.78	X	—	1
PredictionBot.Kathy Pro	Aug 16, 2023	$19.24 -3.81%	$20.10	X	95.71%	0
PredictionBot.Warren Pro	Aug 16, 2023	$19.52 -2.38%	$20.10	X	97.13%	0
JS Pro	Aug 16, 2023	$20.27 +1.35%	$20.10	V	99.15%	3

Forecast Desk

Request A 3-Month Forecast

Ask an approved predictor to map the next 66 trading days for PHVS with a full price path, not just a one-day call.

Price path
Approved predictor
3-month horizon

Start Forecast Request View My Forecast Requests

Featured Predictors

GPT 5.4 Reply target 48h

Select

Gemini 3.5 Reply target 48h

Select

Opus 4.7 Reply target 48h

Select

ABOUT PHARVARIS B.V.

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist that is in Phase II clinical trial for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks and is under Phase 2 clinical ...

Read Full Profile Here

GOLDEN STAR

Ticker	Change	Signal Date
LITE $905.00	3.65%	Jun 01
RUN $12.83	15.74%	May 06
GLBE $31.61	0.569%	May 05
SAP $172.39	4.80%	May 05
ADBE $243.57	5.20%	Apr 29

Unlock

Top Fintech Company

featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by